Britain and America have announced a major trade agreement that will preserve no import taxes on British drug shipments going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to raise expenditure on medicines through the National Health Service (NHS). This commitment ensures that duties on these key products will be held at nothing for a timeframe of 36 months.
This agreement follows recent statements to dramatically increase import taxes on patented drug products, with potential rates floated reaching double the cost.
"This arrangement between the United Kingdom strengthens the global environment for cutting-edge drugs and introduces much-needed fairness to American-British medicine commerce," a release declared.
Trade Significance
Drugs constitute one of the UK's biggest exports to the America, which is clearly the largest market for leading UK drugmakers.
Statistics reveal that in the year to the end of the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount accounted for a significant portion of British export trade in that period.
"This deal protects jobs, boosts investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a government official remarked.
Key NHS Changes
The agreement includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, repayments topped 20%.
Industry Background
The pact follows a protracted row between the drug companies and the UK government over drug pricing and regulatory access.
This friction were intensified by arguments that American customers were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
